Zoetis (NYSE:ZTS) FY Conference January 12, 2026 01:30 PM ET Company ParticipantsWetteny Joseph - Executive VP and CFOKristin Peck - CEOConference Call ParticipantsChris Schott - AnalystChris SchottGood morning, everybody. I'm Chris Schott from J.P. Morgan, and it's my pleasure to be introducing Zoetis today. From the company, we have a presentation from CEO Kristin Peck, and we'll have Wetteny Joseph, the company's CFO, available for Q&A. So with that, Kristin, happy New Year, and looking forward to the pr ...

Summary of Revolution Medicines FY Conference Call Company Overview - **Company**: Revolution Medicines (NasdaqGS:RVMD) - **Industry**: Biotechnology, specifically focused on oncology and RAS-addicted cancers - **Mission**: To revolutionize treatment for patients with RAS-addicted cancers through innovative targeted medicines [2][3] Core Points and Arguments Clinical Development and Pipeline - Revolution Medicines is advancing in three major RAS-addicted cancers: pancreatic, non-small cell lung, and colorectal cancer [3] - The company has four RAS(ON) inhibitors in clinical trials and a deep pipeline, with eight ongoing or announced registrational phase 3 trials [3] - **Key Investigational Drugs**: - **RMC-6236**: A multi-selective RAS(ON) inhibitor with promising clinical profiles [3][6] - **RMC-6291**: A selective inhibitor for RAS G12C mutations [3] - **RMC-9805**: A selective inhibitor for RAS G12D mutations [3] - **RMC-5127**: A selective inhibitor for RAS G12V mutations [3] Market Need and Unmet Needs - Over 90% of pancreatic ductal adenocarcinoma tumors harbor an oncogenic RAS mutation, indicating a significant need for targeted therapies [4] - Approximately 30% of non-small cell lung cancers and over 50% of colorectal cancers also carry oncogenic RAS mutations, highlighting the unmet need for effective treatments [5] Clinical Trial Highlights - **Pancreatic Cancer**: - RMC-6236 has shown promising clinical durability in second-line treatment settings compared to standard cytotoxic chemotherapy [6][10] - Ongoing trials include RASolute 302, 303, and 304, focusing on various treatment regimens [8][10] - **Non-Small Cell Lung Cancer**: - RMC-6236 is being evaluated in RASolute 301, with encouraging early data from combination therapies [12][13] - RMC-9805 and RMC-6291 are also being explored for their roles in treating specific RAS mutations [13][15] - **Colorectal Cancer**: - The company is pursuing combination studies to maximize clinical impact due to the heterogeneous nature of these cancers [15][16] Innovation and Future Directions - Introduction of a new class of RAS(ON) inhibitors designed to overcome drug resistance, with plans to advance the first compound into clinical trials [19][21] - Continuous investment in research and development to maintain leadership in targeted therapeutics for RAS-addicted cancers [17][22] Financial Position - As of Q3 2025, Revolution Medicines reported a strong financial position with $1.9 billion in cash and an additional $1.75 billion in committed capital from Royalty Pharma [23] - The company is well-positioned for broad execution across its clinical programs and operational capabilities [23] Upcoming Milestones - Key data disclosures for RMC-6236 and RMC-9805 are expected in the first half of 2026, including results from ongoing trials [24][25] - Plans to initiate new registrational trials for both pancreatic and non-small cell lung cancers in 2026 [24][25] Other Important Content - The company emphasizes the importance of data maturity before disclosure, aiming to provide relevant information to support clinical programs [28][30] - Concerns regarding external factors affecting trial outcomes and regulatory processes were acknowledged, highlighting the unpredictability of clinical research [34][36] - The differentiation of ZOLD on RASIB was discussed, noting its favorable tolerability profile and potential as a class-leading compound [39][40] This summary encapsulates the key points from the Revolution Medicines FY Conference Call, focusing on the company's strategic direction, clinical advancements, market needs, and financial health.

Neurocrine Biosciences (NasdaqGS:NBIX) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsEric Benevich - Chief Commercial OfficerKyle Gano - CEOMatt Abernathy - CFOSanjay Keswani - CMOConference Call ParticipantsAnupam Rama - Senior Biotech AnalystAnupam RamaAlrighty, let's go ahead and get started. Welcome, everyone, to the 44th Annual J.P. Morgan Healthcare Conference. My name's Anupam Rama. I am one of the Senior Biotech Analysts here at J.P. Morgan. I'm joined by my squad, Ratih Phinney, Pr ...

BillionToOne (NasdaqGS:BLLN) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsCasey Woodring - VP of Equity ResearchOguzhan Atay - Co-Founder, CEO and Board ChairRoss Taylor - CFOCasey WoodringAll right, great. Welcome, everybody, to the JPMorgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team, pleased to be joined by the management team at BillionToOne. We're going to do the standard 40-minute slot, corporate presentation, Q&A afterwards. Not much mo ...

InnovAge (NasdaqGS:INNV) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsBen Adams - CFOPatrick Blair - CEOBen Rossi - Head of European Medtech & ServicesBen RossiAll right. Thank you so much. First and foremost, thank you for all of us joining us in here in person in the room, and for those who are joining us via webcast, my name is Ben Rossi, and I'm the Healthcare Facilities Analyst here at J.P. Morgan. We're excited to be welcoming InnovAge back to the stage this morning. With us here tod ...

Sanofi (NasdaqGS:SNY) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsHouman Ashrafian - EVP and Head of R&DFrançois-Xavier Roger - CFOPaul Hudson - CEOConference Call ParticipantsRichard Vosser - AnalystRichard VosserWelcome to the J.P. Morgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst with J.P. Morgan. It's my great pleasure to introduce Sanofi from the conference. We have three of the very senior management here to entertain us now: Paul Hudson, CEO, François-Xavier ...

Summary of ADMA Biologics FY Conference Call Company Overview - **Company Name**: ADMA Biologics - **Ticker Symbol**: ADMA (NASDAQ) - **Industry**: Biologics, specifically plasma-derived products - **Headquarters**: Ramsey, New Jersey; manufacturing in Boca Raton, Florida; plasma center operations in North Carolina - **Key Products**: IVIG products, including Asceniv and Bivigam Financial Performance - **Total Revenue**: Pre-announced $510 million for the fiscal year 2025, with Q4 revenue exceeding $139 million [2][3] - **EBITDA**: Expected to be between $77-$78 million for Q4 2025, with net income projected at over $50 million [3] - **2026 Guidance**: Forecasting $635 million in revenue and $360 million in EBITDA [24] - **2027 Guidance**: First-time guidance of $775 million in revenue and $455 million in EBITDA [24] Product and Market Insights - **Asceniv**: Unique polyclonal immunoglobulin targeting patients with primary immunodeficiency (PI) and respiratory syncytial virus (RSV) [12][13] - **Market Size**: The immunoglobulin market is projected to grow from over $13 billion in 2024 to over $30 billion by 2033 [10] - **Target Patient Population**: Approximately 250,000 patients with PI, with ADMA targeting about 25,000 patients who do not respond well to standard IG therapy [11][12] Strategic Developments - **Plasma Collection Network**: Currently operates 10 plasma centers, divesting three centers while expanding third-party plasma collection from 250 to 280 centers [4][5] - **Yield Enhancement Strategy**: Achieved a 20% increase in manufacturing yield, allowing for more finished goods from the same raw material [19][44] - **FDA Approval**: First company to receive FDA approval for yield enhancement manufacturing strategy [6][19] Growth Opportunities - **Pipeline Expansion**: Plans to submit a pre-IND package for SG01, a new product expected to generate $300-$500 million in revenue [22][23] - **Pediatric Market**: Anticipating label expansion for Asceniv to include pediatric patients aged 2 to 12 [21] - **Distribution Partnerships**: New agreement with McKesson Specialty to enhance distribution capabilities [18] Operational Efficiency - **Cost Management**: Divestiture of plasma centers expected to reduce operating costs by $13-$15 million [25][40] - **Production Mix**: Shift towards higher production of Asceniv, projected to account for 90% of revenue by 2029 [17] Competitive Landscape - **Market Position**: ADMA is the last U.S.-based producer of intravenous immune globulins, insulated from low-cost competition from emerging markets [6] - **Innovation**: Focus on capital-efficient R&D and leveraging proprietary technology for product differentiation [23][38] Conclusion - ADMA Biologics is positioned for significant growth with a strong financial outlook, innovative product offerings, and strategic operational efficiencies. The company is focused on expanding its market share in the U.S. while exploring future opportunities in pediatric care and new product development.

Summit Therapeutics (NasdaqGM:SMMT) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsDavid Gancarz - Chief Business and Strategy OfficerMaky Zanganeh - President and Co-CEOMaky ZanganehGood afternoon. Thank you for joining us today, and thank you to J.P. Morgan for having us today to present at this conference. I'm Dr. Maky Zanganeh, President and Co-CEO at Summit Therapeutics. Bob Duggan, Chairman and Co-CEO at Summit Therapeutics. I'm honored to go over the latest update for Summit, our lead ...

Inspire Medical Systems (NYSE:INSP) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsNone - Video NarratorTim Herbert - CEOConference Call ParticipantsRobert Marcus - Managing Director and Senior AnalystRobert MarcusAll right, let's get started. I'm Robbie Marcus, the MedTech analyst at JPMorgan. Very happy to introduce Tim Herbert, the CEO of Inspire, for our next presentation. Tim will do some presentation followed by Q&A. Tim.Tim HerbertVery good.Thanks, Robbie. And thanks for having us aga ...

Pfizer (NYSE:PFE) FY Conference January 12, 2026 12:45 PM ET Company ParticipantsAlbert Bourla - Chairman and CEOConference Call ParticipantsChris Schott - AnalystChris SchottGood morning, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be hosting this fireside chat with Albert Bourla, Chairman and CEO of Pfizer. Albert, happy New Year. Great to be speaking with you again today. I know you wanted to make some opening remarks, then we'll jump into the discussion from there.Albert BourlaOf ...